Speakers

Dr. Mueller is Founder and Chief Scientific Officer of Codagenix Inc. He earned his BS in Biology and a MS in Genetics, Developmental Biology, Biochemistry from the University of Cologne, Germany and his PhD in Molecular Microbiology from Stony Brook University. During his time at Stony Brook in the early 2000’s he and his collaborators were early adopters of the budding field of synthetic virology. The work ultimately resulted in the development of a rational computer-aided platform to design synthetic, live attenuated vaccine viruses – a method they dubbed SAVE (Synthetic Attenuated Virus Engineering) (Coleman et al., Science 2008). Inspired by the promise the SAVE technology holds he founded Codagenix Inc. to develop improved live attenuated human animal vaccines (LAVs).  Dr. Mueller has served as primary investigator on multiple government and venture funded vaccine development programs resulting in the development of LAV candidates for human, swine, and canine influenza viruses, SARS-CoV2, Zika, dengue, yellow fever, respiratory syncytial virus, poliovirus, PRRS virus, FMDV and others. The clinically most advanced Codagenix vaccine program is their SARS-CoV-2 LAV, which has recently completed phase 3 human efficacy trials conducted by the World Health Organization under the Solidarity Vaccines Initiative.